Literature DB >> 12084460

Natural antisense (rTSalpha) RNA induces site-specific cleavage of thymidylate synthase mRNA.

Jianxiong Chu1, Bruce J Dolnick.   

Abstract

The 3' untranslated region (UTR) of rTSalpha RNA is complementary (i.e., antisense) to human thymidylate synthase (TS) RNA. When HEp2 cells (human epidermoid carcinoma) progressed from late-log to plateau phase growth, ribonuclease protection assay (RPA) revealed an inverse correlation between the levels of rTSalpha RNA and TS mRNA, suggesting a possible effect of rTSalpha RNA on TS mRNA levels. HEp2 cells expressing a Tet-On transactivator were transiently co-transfected with pHook-1 and a construct containing rTSalpha (protein and antisense RNA), rTSalphaDelta3' (rTSalpha protein only), rTSalpha-3' (antisense RNA-luciferase) or luciferase. Transfected cells were selected and evaluated for the effects of induced transgene expression on TS mRNA. Induced expression of transfected rTSalpha or rTSalpha-3', but not rTSalphaDelta3' or luciferase, resulted in decreased TS mRNA levels as measured by RPA. These results demonstrated that the antisense region of rTSalpha RNA is necessary and sufficient for this down-regulation of TS mRNA. RPA for TS mRNA also showed the enhanced appearance of two partial-length protected fragments in rTSalpha or rTSalpha-3' transfected cells. RPA stringency evaluations and primer extension assays indicated that TS mRNA is cleaved in vivo in a site-specific manner. These data demonstrate that rTS gene expression likely plays a role in down-regulating TS through a natural RNA-based antisense mechanism.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12084460     DOI: 10.1016/s0925-4439(02)00081-9

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  15 in total

1.  Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium.

Authors:  Linda E Kelemen; Marc T Goodman; Valerie McGuire; Mary Anne Rossing; Penelope M Webb; Martin Köbel; Hoda Anton-Culver; Jonathan Beesley; Andrew Berchuck; Sony Brar; Michael E Carney; Jenny Chang-Claude; Georgia Chenevix-Trench; Daniel W Cramer; Julie M Cunningham; Richard A Dicioccio; Jennifer A Doherty; Douglas F Easton; Zachary S Fredericksen; Brooke L Fridley; Margaret A Gates; Simon A Gayther; Aleksandra Gentry-Maharaj; Estrid Høgdall; Susanne Krüger Kjaer; Galina Lurie; Usha Menon; Patricia G Moorman; Kirsten Moysich; Roberta B Ness; Rachel T Palmieri; Celeste L Pearce; Paul D P Pharoah; Susan J Ramus; Honglin Song; Daniel O Stram; Shelley S Tworoger; David Van Den Berg; Robert A Vierkant; Shan Wang-Gohrke; Alice S Whittemore; Lynne R Wilkens; Anna H Wu; Joellen M Schildkraut; Thomas A Sellers; Ellen L Goode
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-06-22       Impact factor: 4.254

2.  A common insertion/deletion polymorphism of the thymidylate synthase (TYMS) gene is a determinant of red blood cell folate and homocysteine concentrations.

Authors:  Carmel Kealey; Karen S Brown; Jayne V Woodside; Ian Young; Liam Murray; Colin A Boreham; Helene McNulty; J J Strain; Joseph McPartlin; John M Scott; Alexander S Whitehead
Journal:  Hum Genet       Date:  2005-01-29       Impact factor: 4.132

3.  Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies.

Authors:  D Meulendijks; E A Rozeman; A Cats; K Sikorska; M Joerger; M J Deenen; J H Beijnen; J H M Schellens
Journal:  Pharmacogenomics J       Date:  2016-12-20       Impact factor: 3.550

4.  Regulation of fibroblast growth factor-2 by an endogenous antisense RNA and by argonaute-2.

Authors:  Leigh-Ann MacFarlane; Ying Gu; Alan G Casson; Paul R Murphy
Journal:  Mol Endocrinol       Date:  2010-03-02

5.  Chromatin-remodeling factors mediate the balance of sense-antisense transcription at the FGF2 locus.

Authors:  Lori A McEachern; Paul R Murphy
Journal:  Mol Endocrinol       Date:  2014-02-19

6.  Genetic variant rs16430 6bp > 0bp at the microRNA-binding site in TYMS and risk of sporadic breast cancer risk in non-Hispanic white women aged ≤ 55 years.

Authors:  Xiaoxiang Guan; Hongliang Liu; Jingfang Ju; Yangkai Li; Peng Li; Li-E Wang; Abenaa M Brewster; Thomas A Buchholz; Banu K Arun; Qingyi Wei; Zhensheng Liu
Journal:  Mol Carcinog       Date:  2013-10-26       Impact factor: 4.784

7.  Association of thymidylate synthase gene with endometrial cancer risk in a Chinese population.

Authors:  Wang-Hong Xu; Ji-Rong Long; Wei Zheng; Zhi-Xian Ruan; Qiuyin Cai; Jia-Rong Cheng; Gen-Ming Zhao; Yong-Bing Xiang; Xiao-Ou Shu
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-02-03       Impact factor: 4.254

8.  Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer.

Authors:  Si-Qi Dong; Tong-Min Wang; Jiang-Bo Zhang; Yong-Qiao He; Wen-Qiong Xue; Zi-Yi Wu; Da-Wei Yang; Lian-Jing Cao; Jing-Wen Huang; Xi-Zhao Li; Pei-Fen Zhang; Xiao-Hui Zheng; Wei-Hua Jia
Journal:  Cancer Res Treat       Date:  2020-12-02       Impact factor: 4.679

9.  RNA interference is not involved in natural antisense mediated regulation of gene expression in mammals.

Authors:  Mohammad Ali Faghihi; Claes Wahlestedt
Journal:  Genome Biol       Date:  2006-05-09       Impact factor: 13.583

10.  New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progression.

Authors:  Raymond A Clarke; Zhongming Zhao; An-Yuan Guo; Kathrein Roper; Linda Teng; Zhi-Ming Fang; Hema Samaratunga; Martin F Lavin; Robert A Gardiner
Journal:  PLoS One       Date:  2009-03-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.